This is promising news.
I first heard about Norudca when I got diagnosed more than 10 years ago. Hopefully the long wait is over and this turns out to be a real cure or treatment.
List of accepted late-breaker EASL abstracts:
Here is the Google AI summary:
Michael Trauner will be presenting on Norucholic acid for the treatment of primary sclerosing cholangitis at the EASL Congress 2025. This oral presentation, titled “Norucholic acid for the treatment of primary sclerosing cholangitis: 96-week analysis of a pivotal phase 3 trial” will be part of the EASL Congress in Amsterdam. The presentation is scheduled to take place on May 7-10, 2025
I’m convinced that the clinical trial phase 3 results are going to be positive.
The big question is when is Norudca going to be available (in the pharmacy near you).
In Europe this may happen soon since the company operates in Europe and trials were done in Europe.
EA pharma acquired licensing rights in Japan, so presumably it will be available in Japan in the near future.
But I think there is no US company yet that has the licensing rights. It cannot be sold in the US if there is no US company with the necessary rights (could be local branch of dr falk).
US based patients may need to travel to Europe to get access to Norudca, though I’m not sure if Norudca would be available outside of the national healthcare system.